Scientists have identified a drug combination that could be effective against malignant rhabdoid tumours, a cancer type most common in infants and toddlers.
The research team, led by Dr Paul Huang, identified two genes, PDGFRA and FGFR1, which were more active in patients with malignant rhabdoid tumours and seemed to play an important role in driving growth of the cancers. These clues led them to identify new targeted treatments that might be more effective than chemotherapy.
The research was funded by Sarcoma UK, the Institute of Cancer Research and Cancer Research UK.
Sarah McDonald, Sarcoma UK's Director of Research, said: “We are delighted that Sarcoma UK-funded research has made this step forward to identify potential treatment for malignant rhabdoid tumours. We look forward to the outcomes of the trial and the potential this will have for sarcoma patients. The Sarcoma UK research programme is helping find answers sooner."